Possibly, I believe we could benefit from a restructure.
The business is now at a stage where separate business units with defined responsibilities and management could be a significant benefit and provide greater focus going forward.
I could see three separate units each requiring different management skill sets:
1 - Research
2 - Manufacturing
3 - Commercial operations
Stem Cell Therapy advancements, page-435
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.015(3.23%) |
Mkt cap ! $94.30M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 47.0¢ | 44.8¢ | $101.0K | 221.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6739 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 9799 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |